Roth Capital Reiterates Buy on Coya Therapeutics, Maintains $12 Price Target

Coya Therapeutics, Inc.

Coya Therapeutics, Inc.

COYA

0.00

Roth Capital analyst Boobalan Pachaiyappan reiterates Coya Therapeutics (NASDAQ: COYA) with a Buy and maintains $12 price target.